A Placebo-Controlled, Double-Blind, Randomized, Multi-center Study to Assess the Effects of Dronedarone 400 mg BID on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement.

Trial Profile

A Placebo-Controlled, Double-Blind, Randomized, Multi-center Study to Assess the Effects of Dronedarone 400 mg BID on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 11 Feb 2013

At a glance

  • Drugs Dronedarone (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms ODYSSEUS
  • Sponsors Sanofi
  • Most Recent Events

    • 24 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 Oct 2011 Planned end date changed from 1 Jun 2012 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 05 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top